Fierce Pharma3d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Fierce Pharma3d
Viking pays $150M to recruit CordenPharma for obesity drug manufacturing saga
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
Zacks Investment Research on MSN2d
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
Viking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and ...
Healio9d
Subcutaneous adjuvant regimen for breast cancer reduces ‘time toxicity’ of treatment
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
Halozyme Therapeutics: Steady Growth In A Challenged Market
Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...
Zacks Investment Research on MSN1d
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Becker's Hospital Review2d
HIV drug could offer yearlong protection with a single shot
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...
Zacks.com on MSN2d
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...